Compare PRTH & DAWN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRTH | DAWN |
|---|---|---|
| Founded | 2005 | 2018 |
| Country | United States | United States |
| Employees | 1019 | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 451.1M | 2.2B |
| IPO Year | N/A | 2021 |
| Metric | PRTH | DAWN |
|---|---|---|
| Price | $4.96 | $21.31 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 10 |
| Target Price | $8.33 | ★ $26.00 |
| AVG Volume (30 Days) | 279.5K | ★ 5.7M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $158,182,000.00 |
| Revenue This Year | $10.18 | $53.52 |
| Revenue Next Year | $9.33 | $27.10 |
| P/E Ratio | $10.38 | ★ N/A |
| Revenue Growth | N/A | ★ 20.60 |
| 52 Week Low | $4.44 | $5.64 |
| 52 Week High | $8.89 | $21.40 |
| Indicator | PRTH | DAWN |
|---|---|---|
| Relative Strength Index (RSI) | 31.06 | 82.10 |
| Support Level | $4.44 | $6.45 |
| Resistance Level | $6.01 | N/A |
| Average True Range (ATR) | 0.23 | 0.55 |
| MACD | -0.06 | 1.02 |
| Stochastic Oscillator | 7.65 | 99.21 |
Priority Technology Holdings Inc is a provider of merchant acquiring and commercial payment solutions to small and medium business enterprises in the United States. The company has three reportable segments which are SMB Payments, B2B Payments, and Enterprise Payments. SMB Payments segment which generates the majority of revenue provides full-service acquiring and payment-enabled solutions for B2C transactions, leveraging Priority's proprietary software platform, distributed through ISO; the B2B Payments segment provides AP automation solutions to corporations, software partners, & industry FIs: and Enterprise Payments segment provides embedded payment & treasury solutions to enterprise customers to modernize legacy platforms & accelerate software partners' strategies to monetize payments.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY301 is an antibody drug conjugate (ADC) that has shown antitumor activity in preclinical models.